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hip, but no differences were observed at MCP joints com-
pared to ACPA-negative patients. However, ACPA-positive 
patients displayed higher disease activity and disability 
than ACPA-negative patients. After adjustment for gender, 
age, body mass index, and other bone-related variables, the 
presence of ACPA remained significantly associated with 
lower BMD at the lumbar spine, femoral neck, and hip 
but not at MCP joints. Disease activity was not associated 
with baseline bone mass. Our data reinforce the previous 
preclinical findings suggesting that the systemic bone loss 
detected at the initial phases of early ACPA-positive arthri-
tis is independent of inflammatory status and, therefore, 
could be mediated by ACPA.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory 
disease characterized by persistent inflammation of the 
synovial membrane and joint destruction, bone loss, and 
systemic complications. Skeletal changes in RA include 
juxta-articular bone erosions, periarticular bone loss, and 
systemic osteoporosis [1, 2]. Until a few years ago, rheu-
matologists assumed that osteoporosis in RA was mainly 
derived from chronic inflammation, use of glucocorti-
coids or some disease-modifying anti-rheumatic drugs 
(DMARDs), and immobilization. However, in the light 
of current knowledge, bone destruction in arthritis seems 
to be caused by two main mechanisms: inflammation and 
autoimmunity [2, 3].
Pro-inflammatory cytokines such as TNF-α, IL-1, IL-6, 
and IL-8 enhance the proliferation and differentiation of the 
Abstract Since the previous studies showed that anti-
citrullinated protein antibodies (ACPA) can induce osteo-
clasts differentiation and activation, even before arthri-
tis onset, the aim of our study was to determine whether 
ACPA-positivity is associated with lower bone mineral 
density (BMD) at baseline visit of a register of early arthri-
tis (EA) patients. The study population comprised 578 
patients (80% females) from our EA clinic with a median 
disease duration, 5.1 months (p25–p75: 6–8); median age, 
53.6 years (41.9–66.1), 38% ACPA-positive, and 55% ful-
filling 2010 criteria for rheumatoid arthritis. BMD was 
measured using dual X-ray absorptiometry at lumbar 
spine, hip, and metacarpophalangeal (MCP) joints of the 
non-dominant hand to evaluate both systemic and juxta-
articular bone mass. ACPA titers were determined through 
enzyme immunoassay. The effect of ACPA on BMD was 
analyzed using multivariable analysis based on generalized 
linear models adjusted for various confounders. ACPA-pos-
itive patients showed lower bone mass at lumbar spine and 
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monocyte-macrophage lineage, increasing the population 
of mature osteoclasts [2, 4, 5]. Indeed, the existence of an 
inflammatory microenvironment from the earliest stages of 
RA had been proposed to be responsible for the appearance 
of bone erosions and systemic osteoporosis in these phases 
of the disease [1, 6].
On the other hand, the presence of rheumatoid factor 
(RF) and, especially, anti-citrullinated protein autoantibod-
ies (ACPA) is another important risk factor for the develop-
ment of bone erosions and osteoporosis in RA [2, 3, 7]. In 
this regard, ACPA can be detected up to 5–10 years before 
clinical synovitis develops and, especially those with anti-
citrullinated vimentin and enolase specificities, have been 
described to induce formation and activation of osteoclasts 
in vitro and in a mouse model [5, 8]. In fact, Kleyer et al. 
have recently demonstrated a decrease in cortical bone 
mass in a limited population of healthy ACPA-positive sub-
jects without any joint symptom [9].
These interesting data suggest that the presence of 
ACPA could partially explain the bone loss detected in the 
initial phases of chronic inflammatory arthritis. Thus, in 
this work, we analyzed whether the presence of ACPA is 
associated with differences in bone mineral density (BMD) 
at hip and lumbar spine to assess systemic bone density and 
at metacarpophalangeal (MCP) joints to measure juxta-




A cross-sectional study was performed in 578 patients with 
suspected early arthritis submitted to the Princesa Early 
Arthritis Register Longitudinal (PEARL) study, which 
started in 2001 and in which data are recorded by protocol 
at five structured visits (baseline, 6, 12, 24, and 60 months). 
The information registered includes, age, gender, race, dis-
ease duration at the beginning of follow-up, smoking status, 
menopause, family history of RA; therapies received and 
cumulative prednisone dose at recruitment; global disease 
activity on a 100-mm visual analogue scale assessed by 
both the patient and the physician; number of swollen and 
tender joints (28-joint count), and the score of the Span-
ish version of the Health Assessment Questionnaire [10]. 
Laboratory tests include blood cell counts, general bio-
chemistry, erythrocyte sedimentation rate (ESR), C-reac-
tive protein (CRP), rheumatoid factor (RF; measured by 
nephelometry, positive >20  IU/ml), and anti-citrullinated 
peptide antibodies (ACPA; assessed by enzyme immuno-
assay, see below). For this study, disease activity was esti-
mated using the 28-joint disease activity score (DAS28) 
calculated with the ESR [11] and the Hospital Universitario 
de La Princesa Index (HUPI) [12], that is an index for the 
assessment of disease activity in chronic polyarthritis that 
includes the same domains as DAS28 and SDAI but cor-
rected by gender when considering tender joint count and 
erythrosedimentation rate (ESR). HUPI is calculated as the 
sum of four variables (graded 0–3): 28 tender and swol-
len joint counts, global disease assessment by physician 
and acute phase reactants. The score of these variables was 
based in their quartile distribution in the population used to 
describe this index [12, 13]. A more detailed description of 
the PEARL study has been previously published [14].
For this work, we used only information from the base-
line visit of patients included in the register from February 
2002, when we included BMD measurements in the regis-
ter protocol, until January 2016.
BMD measurements
BMD was assessed using dual-energy X-ray absorptiom-
etry (DXA) on a Hologic©QDR-4500 Elite (Bedford, MA, 
USA) at lumbar spine (LS) and hip. Furthermore, in 2004, 
we started to scan BMD at non-dominant hand to study the 
effect of joint swelling on juxta-articular bone mass.
Specifically, we analyzed BMD from L2 to L4, total 
hip (TH) and femoral neck (FN), and at hand, we assessed 
BMD from second to fifth MCP joints, as previously 
described [15]. BMD is expressed in g/cm2, except for the β 
coefficients in the multivariable analysis that are expressed 
in mg/cm2 to obtain more affordable values.
ACPA and anti–mutated citrullinated vimentin 
antibodies
ACPA were measured using a second-generation anti-
citrullinated cyclic peptide enzyme immunoassay (EIA; 
Euro-Diagnostica Immunoscan RA; positive >50  U/ml) 
until October 2010 and then using a third-generation EIA 
(QUANTA Lite CCP3 IgG and IgA, Inova Diagnostics; 
positive >40 U/ml). Both methods are EIA, but the third-
generation analysis is able to detect IgA ACPA in addi-
tion to IgG antibodies, with no other important differences 
between them. For this study, ACPA levels were classified 
as negative if below the manufacturer’s limit, low if above 
this limit but below the median of the positive population 
(500  U/ml for the Euro-diagnostica kit and 350  U/ml for 
the Quanta Lite Kit) and high when above the median of 
the positive population.
In addition, we assessed anti-mutated citrullinated 
vimentin IgG antibodies (MCV-ACPA) through a quan-
titative EIA (ORG548 anti-MCV, Orgentec Diagnostika 
GmbH, Mainz, Germany; positive >20 U/ml). MCV-ACPA 




PEARL study is conducted according to the principles 
expressed in the Helsinki Declaration of 1983 and it was 
approved by the Research Ethics Committee of Hospital 
Universitario La Princesa. All patients signed a written 
consent at study entry.
Statistical analysis
The descriptive analysis was performed by calculating the 
mean and standard deviation (SD) of quantitative variables 
with a normal distribution. The median and the interquar-
tile range (IQR) were calculated for those variables with 
no normal distribution. Estimation of the proportions was 
used to describe qualitative variables. Student’s t test was 
applied to compare the means of variables with a normal 
distribution and Mann–Whitney test used for variables that 
did not present normal distribution. The χ2 test was used for 
qualitative variables.
We first used the t test to determine whether the dif-
ferences in BMD at the different anatomic sites between 
ACPA-positive and ACPA-negative patients were statis-
tically significant. However, since there were significant 
differences between ACPA-positive and ACPA-negative 
populations in variables that can influence BMD (Table 1), 
we performed a multivariable analysis through general-
ized linear models using the glm command of Stata 12.1 
for Windows (Stata Corp LP, College Station, TX, USA) 
for each location. Variables that were different between 
the two populations (Table 1) as well as those considered 
relevant to explain BMD (age, body mass index [BMI], 
smoking, disease activity, and cumulative prednisone dose 
at baseline) were included in the initial models. The final 
models were obtained through manual stepwise backward 
elimination of variables by means of the Bayesian infor-
mation criterion, removing all variables with p > 0.15. The 
only exception was ACPA status, which was maintained in 
all the models, even though it did not reach a p ≤ 0.15. We 
also performed a sensitivity analysis by repeating the mul-
tivariable analysis both in the population fulfilling the 2010 
RA criteria and in patients who did not meet these criteria 
separately [16].
Significance was set to p < 0.0125 due to multiple com-
parisons in the bivariate analysis and to p < 0.05 in the mul-
tivariable analysis, since the latter approach ensures enough 
adjustment to avoid associations by chance.
Results
Differences between ACPA-positive and ACPA-negative 
patients
More ACPA-positive than ACPA-negative patients fulfilled 
the 2010 RA criteria [16] (Table 1). Patients not fulfilling 
Table 1  Characteristics of the population
n number, IQR interquartile range, ACPA anti-citrullinated protein antibodies, p50 50th percentile or median, SD standard deviation, BMI body 
mass index, NA not available, RA rheumatoid arthritis, RF rheumatoid factor, DAS28 disease activity score based on a 28-joint count, HUPI Hos-
pital Universitario La Princesa Index, HAQ Health Assessment Questionnaire, MCP metacarpophalangeal joints
Total (n = 578) ACPA+ (n = 220) ACPA− (n = 358) p
Female, n (%) 458 (79.2) 187 (85.0) 271 (75.7) 0.007















BMI (p50 [IQR]) 26.0 [23.0–29.1] 25.0 [22.5–28.9] 26.4 [23.5–29.3] 0.005
Menopause (%) no/yes/NA 60.1/37.6/2.3 58.1/38.8 /3.1 61.2/36.9/1.9 0.548
Prednisone use, n (%) 130 (22.5) 56 (25.4) 74 (20.7) 0.193
Cumulative prednisone dose (mg; p50 [IQR]; 
mean ± S)
0 [0–125] 168 ± 445 0 [0–125] 159 ± 436 0 [0–125] 174 ± 451 0.749
Disease duration (months; p50 [IQR]) 5.0 [2.8–8.2] 5.5 [3.1–8.8] 4.7 [2.5–7.8] 0.017
2010 RA criteria, n (%) 316 (54.7) 196 (89.1) 120 (33.5) <0.001
RF, n (%) 254 (43.9) 171 (77.7) 83 (23.2) <0.001
DAS28(p50 [IQR]) 4.1 [3.2–5.4] 4.3 [3.3–5.6] 4.1 [3.1–5.1] 0.054
HUPI 6.5 [9–4] 7 [10–4] 6 [9–4] 0.0230
HAQ(p50 [IQR]) 0.875 [1.5–0.375] 0.875 [1.625–0.375] 0.875 [1.5–0.375] 0.795
Swollen MCP (2nd to 4th; p50 [IQR]) 0 [0–1] 1 [0–2] 0 [0–1] 0.004
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these criteria suffered from undifferentiated arthritis (UA, 
65.8%), spondyloarthropathies (8.9%), osteoarthritis 
(8.5%), connective tissue disorders (4.3%), and miscella-
neous conditions (e.g., gout or viral arthritis) (22.5%). RF 
positivity, female gender, longer disease duration, lower 
BMI, and swollen MCP joints were also significantly more 
frequent in ACPA-positive patients (Table  1). In addi-
tion, this population showed a higher disease activity that 
reached statistical significance with HUPI and was almost 
significant when estimated by DAS28 (Table  1). Differ-
ences in the percentage of patients treated with glucocor-
ticoids and the cumulative prednisone dose used were not 
significant (Table 1).
ACPA-positive patients show lower systemic BMD 
than ACPA-negative
ACPA-positive patients showed significantly lower unad-
justed BMD at LS as well as at TH and FN (Fig.  1a–c). 
No significant differences were observed for the MCP 
joints (Fig. 1d). To determine whether differences in BMD 
between ACPA-positive and negative patients were a true 
effect of the autoantibodies or a bias related to differences 
in the characteristics of both populations, we fitted a mul-
tivariable analysis. In addition, we included in the model 
other variables that are known to have an influence on 
BMD, such as menopausal status, age, BMI, or cumulative 
glucocorticoid dose at the time of BMD measurement.
As expected, variability in BMD was significantly 
associated with gender, age, menopause, and BMI 
(Table  2). After adjustment for these variables, ACPA-
positivity remained as an independent variable associated 
with lower values of BMD at LS, FN, and TH (Table 2). 
Disease duration at baseline, fulfillment of 2010 RA 
criteria, and disease activity, even when estimated with 
HUPI, that is more accurate than DAS28 [13], were 
excluded from the final models, since they did not signifi-
cantly associate with differences in BMD at these loca-
tions and did not improve the models (data not shown).
As at the other locations, variations in BMD at MCP 
joints were explained by gender, age, and BMI (Table 2). 
Furthermore, fulfillment of 2010 RA criteria was associ-
ated with a tendency toward lower BMD at MCP joints 
(Table  2). Surprisingly, the number of swollen MCP 
joints at the time of BMD measurement was not asso-
ciated with lower bone mass at this location (data not 
shown).
A sensitivity analysis performed separately with the 
patients fulfilling 2010 RA criteria reproduced the find-
ings described above (Supplementary data).
MCV-ACPA-positivity is associated with lower systemic 
BMD
Finally, since MCV-ACPA have been associated with 
activation of osteoclasts and cortical osteoporosis in 
healthy individuals [9], we tested whether these antibod-
ies were associated with lower BMD. The MCV-ACPA 
titers correlated significantly with ACPA levels (Fig. 2a). 
In addition, when we split our population according to 
MCV-ACPA status, BMD showed a pattern similar to 
that of ACPA (Fig.  2b). After adjustment for confound-
ers, MCV-ACPA-positivity showed a similar tendency 
toward lower BMD at the same locations as total ACPA 
(Table 3).
Fig. 1  Systemic bone mineral density in anti-citrullinated protein 
antibodies (ACPA) positive patients. Panels represent distribution 
of bone mineral density (BMD) at different locations in patients 
included in this study: lumbar spine (a), femoral neck (b), total hip 
(c), and average of second to fifth metacarpophalangeal (MCP) joints 
(d). Data are presented as interquartile range (p75 upper edge, p25 
lower edge, p50 midline in the box), p95 (line above the box) and p5 
(line below the box). Dots represent outliers. Statistical significance 




Table 2  Effect of ACPA and other variables on bone mineral density (mg/cm2) at lumbar spine, hip, and MCP joints
n number, coef. coefficient, CI confidence interval, ACPA anti-citrullinated protein antibodies, MCP metacarpophalangeal joints, BMI body mass 
index, RA rheumatoid arthritis, N.I. not included
Lumbar spine (n = 553) Femoral neck (n = 566) Total hip (n = 566) MCP 2nd–5th (n = 389)
β coef. (95% CI) p β coef. (95% CI) p β coef. (95% CI) p β coef. (95% CI) p
ACPA-positive −36 (−59; −12) 0.003 −23 (−41; − 5) 0.014 −25 (−50; −1) 0.046 2 (−6; 11) 0.572
Female −32 (−64; 0) 0.053 −25 (−50; 0) 0.051 −64 (−98; −30) < 0.001 −24 (−34; −13) <0.001
Age (years)
 <45 Ref – Ref – Ref – Ref –
 45–65 −44 (−75; −13) 0.005 −54 (−79; −30) <0.001 −49 (−82; −16) 0.003 −3 (−13; 7) 0.572
 >65 −75 (−110; −40) <0.001 −134 (−161; −107) <0.001 −117 (−155; −81) <0.001 −38 (−49; −27) <0.001
BMI (kg/m2) 5 (3; 8) <0.001 8 (6; 10) <0.001 10 (8; 13) <0.001 2 (2; 3) <0.001
Menopause
 No Ref – Ref – Ref – Ref –
 Yes −69 (−99; −39) <0.001 −53 (−77; −30) <0.001 −50 (−81; −18) 0.002 −21 (−31; −12) <0.001




N.I N.I N.I −8 (−17; 0) 0.050
Fig. 2  Correlation and comparative effect of anti-mutated citrul-
linated vimentin (MCV-ACPA) and anti-citrullinated proteins anti-
bodies (ACPA) on lumbar spine bone mineral density. a Correlation 
between ACPA and MCV-ACPA levels. b Distribution of BMD at 
lumbar spine of patients from the Princesa Early Arthritis Register 
Longitudinal study according to ACPA levels (left panels) or MCV-
ACPA levels (right panels). Data are presented as interquartile range 
(p75 upper edge, p25 lower edge, p50 midline), p95 (line above the 
box), and p5 (line below the box) in a and upper panels of b. Dots 
represent the outliers. Statistical significance was estimated using the 
Kruskal–Wallis test and was set at p < 0.05. In the lower panels of b, 
data are shown as the linear prediction with 95% confidence intervals 





Our results are important, since the previous studies that 
demonstrated this association were performed in  vitro, in 
mice [5, 8] or in a small population of healthy individu-
als [9] where the influence of confounders could not be 
excluded. Recently, Bugatti et  al. have published a study 
performed in a clinical setting demonstrating that the pres-
ence of ACPA and high RF levels is associated with lower 
systemic BMD, but not at juxta-articular bone level, in an 
early untreated RA population [17].
The higher prevalence of osteoporosis in RA patients 
than in the healthy general population remains common 
in the long-term disease [18]. The main explanations for 
this finding were thought to be the prolonged use of gluco-
corticoids and the persistent inflammatory activity during 
follow-up [19]. However, our previous data suggested that 
glucocorticoids may even have a beneficial effect on BMD 
when they are used over short periods to resolve inflamma-
tion in the early stages of the disease [20]. In that work, we 
analyzed the effect of disease activity and glucocorticoids 
in the variation of BMD in patients with RA after 2 years 
of follow-up. Cumulative disease activity was significantly 
associated with bone loss at lumbar spine and it showed a 
trend to significance at hip and ultradistal forearm, but no 
association was observed at mid forearm which is mainly 
cortical bone [20]. By contrast, 2 year cumulative dose of 
glucocorticoids was not associated with any significant 
effect on bone mass at hip, lumbar spine or hand [20]. 
In the present work, we did not observe any association 
between BMD and glucocorticoid use or disease activity. It 
is likely that the short disease duration avoids the detection 
of the deleterious effect of these variables on bone mass.
The presence of ACPA is thought to lead to local and 
systemic osteoporosis through osteoclasts activation even 
in the absence of chronic inflammation, although whether 
this effect is more intense in cortical [21] or trabecular [5] 
bone remains unclear. Our data support an inflammation-
independent effect of ACPA based on the following rea-
sons: (a) BMD measurements were performed early after 
the onset of arthritis; (b) The variation in BMD was not 
explained by the intensity of disease activity or disease 
duration. Nonetheless, this work does not clarify whether 
ACPA affect mainly cortical or trabecular bone, since the 
effect observed in our patients was most significant at the 
hip and LS, where bone mineral content is a mixture of 
cortical and trabecular bone.
Interestingly, Bugatti et al. found an association between 
the presence of ACPA and low BMD, defined as Z score 
≤ −1 SD, at lumbar spine and total hip, an effect that was 
reinforced by the presence of high levels of RF [17].
Curiously, in our study, bone loss was more evidently 
associated with total ACPA than with MCV-ACPA. It may 
be related to technical issues in detection of MCV-ACPA 
compared with ACPA, leading to some discordance in their 
titers (Fig. 2a). However, the most likely explanation is that 
Table 3  Effect of MCV-ACPA and other variables on bone mineral density (mg/cm2) at lumbar spine, hip, and MCP joints
coef coefficient, CI confidence interval, MCV-ACPA anti-mutated citrullinated vimentin antibodies, ref. reference, BMI body mass index, RA 
rheumatoid arthritis, N.I. not included, MCP metacarpophalangeal joints
Lumbar spine (n = 523) Femoral neck (n = 537) Total hip (n = 537) MCP 2nd–5th (n = 372)
β coef. (95% CI) p β coef. (95% CI) p β coef. (95% CI) p β coef. (95% CI) p
MCV-ACPA level
 Negative Ref – Ref – Ref – Ref
 Low −27 (−58; 4) 0.086 −17 (−40; 7) 0.160 −30 (−54; −5) 0.018 7 (−4; 18) 0.218
 High −30 (−61; 1) 0.059 −9 (−33; 14) 0.447 −2 (−27; 22) 0.865 3 (−9; 13) 0.712
Female −30 (−65; 6) 0.099 −23 (−50; 4) 0.092 −48 (−77; −20) 0.001 −24 (−35; −13) <0.001
Age (years)
 <45 Ref – Ref – Ref – Ref –
 45–65 −45 (−77; −12) 0.007 −55 (−80; −30) <0.001 −31 (−57; −5) 0.021 −5 (−15; 5) 0.331
 >65 −68 (−106; −30) <0.001 −134 (−163; −105) <0.001 −105 (−135; −75) <0.001 −40 (−51; −28) <0.001
 BMI (kg/m2) 5 (3; 8) <0.001 9 (7; 11) <0.001 11 (9; 13) <0.001 2 (2; 3) <0.001
Menopause
 No Ref – Ref – Ref – Ref –
 Yes −75 (−107; −43) <0.001 −53 (−78; −28) <0.001 −71 (−97; −45) <0.001 −19 (−29; −9) <0.001




N.I N.I N.I −9 (−19; 0) 0.055
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antibodies against citrullinated proteins other than vimentin 
have a similar effect on osteoclasts differentiation and acti-
vation. This is the case of anti-citrullinated enolase anti-
bodies that have recently been associated with osteoclasts 
activation and bone loss in mice [5]. Other ACPA specifi-
cities, such as citrullinated fibrinogen or GRP78, induce 
monocyte or macrophage activation, leading altogether to 
the notion that ACPA have a pathogenic role in osteoporo-
sis seen in patients with rheumatoid arthritis [22].
In addition, to autoimmunity-induced mechanisms, dif-
ferences in bone microenvironment between anatomic 
sites cannot be ruled out. The ability of precursor cells to 
become mature osteoclasts may be affected by variations 
in the availability of osteoclasts precursors, the cytokine 
milieu, and cell–cell interactions [23]. Furthermore, het-
erogeneity in the phenotype of the resultant osteoclasts can 
also determine osteoclastogenic pathways with differences 
in bone resorption [23].
Our study has some limitations. Two different methods 
have been used to assess ACPA along the 14 years of the 
PEARL study. We think that considering ACPA as positive 
or negative or the semi-quantitative method used for nor-
malization of their titers has minimized the impact of this 
issue. In addition, the method used during the last years 
was able to detect IgA and IgG ACPAs, whereas the first 
method only detected IgG. We do not know how this issue 
could affect our findings; nevertheless, osteoclast activa-
tion induced by ACPA has been described to be induced 
by complete ACPA but also by Fab ACPA, suggesting that 
this phenomenon is independent of the Fc fragment [8]. 
Therefore, it is likely that the use of two different methods 
to determine ACPA in our study had a little impact.
The heterogeneity of the population included could 
be considered a drawback of our study. However, similar 
findings were observed when we performed a sensitivity 
analysis separately in patients fulfilling or not the 2010 RA 
criteria. On the contrary, we consider that using a mixed 
population reinforces the effect of ACPA on BMD, since 
this variable proves to be significant in such a heterogene-
ous population independently of the clinical diagnosis.
Finally, we lack data on the age of menopause, a rele-
vant variable for bone mineral density, in 2.3% of patients 
included in the study. There were no significant differences 
in the percentage of patients with menopause and those 
with no available information on menopause status between 
ACPA-positive or ACPA-negative patients, so we consider 
that this issue does not affect significantly our findings of 
association between low bone mass and ACPA-positivity.
In conclusion, our data support the previous observa-
tions, suggesting that ACPA are associated with bone 
loss in patients submitted by suspicion of arthritis, inde-
pendently of the etiology. Further studies are necessary to 
determine their clinical relevance, since, although the effect 
of ACPA on BMD was significant, the long-term clini-
cal impact of these findings is currently unknown. Studies 
exploring whether there are differences in the prevalence of 
osteoporotic fractures between ACPA-positive and negative 
patients would be needed to determine the real impact of 
these findings.
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